Bioasis Technologies Inc. V.BTI

Collaboration with Jansen

[Sniper007]

Collaboration with Jansen (see link below if it works).

Google Bioaf: Collaboration arrangement with Jansen

"Alternatives that may be pursued include potential accretive merger or acquisition opportunities and future financings."

I talked with IR this week and things do seem to be going very, very, well (Psst - Frt, beenthere, Aarcor, maybe you should do the same). Accretive was definitely a word that was used multiple times. 

Acquisition opportunities scare me at this point in the game given that Bioasis has not yet accomplished anything truly worthy of a sp increase. I would like to hear others thoughts on this report released on tuesday from Zacks.

https://finance.yahoo.com/news/bioaf-collaboration-arrangement-janssen-101500677.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAACef_aMS7lyO4tGhnjmLyGWeNmvV7B0QZEV_p_Rm1k8s9KDdRPj0ZOfLrAumDjDWmsD7UUSgsC0tDxV8qFTJTqZYbwZ4kWPREsS5fgy_HmFlQmjR-z9jdv56jBZ6YAlGNVlEw0OjIWuT1YfofZtPLtsF5ivBX5jWTQ8bzdPGdRJI#:~:text=On%20April%2011th%2C%20Bioasis,develop%20and%20commercialize%20new%20products.

[prophetoffact]

This post has been removed in accordance with Community Policy

[prophetoffact]

This post has been removed in accordance with Community Policy

[JDavenport]

What the hell does that have to do with Bioasis, poof? Trivia. Worthless trivia. Meaningless. Apples to oranges to beans and pork. Copy/paste. jd

[prophetoffact]

This post has been removed in accordance with Community Policy

[KayakerBC]

Acquisition opportunities scare me at this point in the game given that Bioasis has not yet accomplished anything truly worthy of a sp increase. I'll repeat what I've said before.  If an "acquisition" is a Contingent Value Rights (CVR) deal, I'll consider it a disaster and will most definitely vote against it. Shadowy Shares: The Dark Side of Contingent Value Rights

[JDavenport]

I absolutely agree with KayakerBC about avoiding an "acquisition" through a Contingent Value Rights (CVR) deal. (His post about CVRs) Bioasis ought to be able to get at least one business deal done of sufficient value to accurately value the entire suite of xB3-enabled commercial opportunities. Even the most modest shareholder expectations have not been met in the entire history of